Sex differences in COPD management

References

• Ntritsos G, Franek J, Belbasis L, et al. Gender-specific estimates of COPD prevalence: a systematic review and meta-analysis. Int J Chron Obstruct Pulmon Dis. 2018;13:1507–1514.
   PubMed Web of Science ®Google Scholar
• Dorner TE, Brath H, Kautzky-Willer A. Sex-specific trends in smoking prevalence over seven years in different Austrian populations: results of a time-series cross-sectional analysis. BMJ Open. 2020;10(9):e035235.
   PubMed Web of Science ®Google Scholar
• Jenkins CR, Chapman KR, Donohue JF, et al. Improving the Management of COPD in Women. Chest. 2017;151(3):686–696.
   PubMed Web of Science ®Google Scholar
• Olié V, Pasquereau A, Assogba FAG, et al. Changes in tobacco-related morbidity and mortality in French women: worrying trends. Eur J Public Health. 2020;30(2):380–385.
   PubMed Web of Science ®Google Scholar
• Sørheim IC, Johannessen A, Gulsvik A, et al. Gender differences in COPD: are women more susceptible to smoking effects than men? Thorax. 2010;65(6):480–485.
   PubMed Web of Science ®Google Scholar
• Duarte-de-Araújo A, Teixeira P, Hespanhol V, et al. Characterisation of morbidity in a COPD hospital cohort. Pulmonology. 2019;25(4):200–207.
   PubMed Web of Science ®Google Scholar
• Sana A, Somda SMA, Meda N, et al. Chronic obstructive pulmonary disease associated with biomass fuel use in women: a systematic review and meta-analysis. BMJ Open Respir Res. 2018;5(1):e000246.
   PubMed Web of Science ®Google Scholar
• Tan WC, Sin DD, Bourbeau J, et al. Characteristics of COPD in never-smokers and ever-smokers in the general population: results from the CanCOLD study. Thorax. 2015;70(9):822–829. .
   PubMed Web of Science ®Google Scholar
• Haghani A, Arpawong TE, Kim JK, et al. Female vulnerability to the effects of smoking on health outcomes in older people. PLoS One. 2020;15(6):e0234015.
   PubMed Web of Science ®Google Scholar
• Gan WQ, Man SF, Postma DS, et al. Female smokers beyond the perimenopausal period are at increased risk of chronic obstructive pulmonary disease: a systematic review and meta-analysis. Respir Res. 2006;7(1):52.
   PubMedGoogle Scholar
• Martinez FJ, Curtis JL, Sciurba F, et al. Sex differences in severe pulmonary emphysema. Am J Respir Crit Care Med. 2007;176(3):243–252.
   PubMed Web of Science ®Google Scholar
• Celli BR, Thomas NE, Anderson JA, et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med. 2008;178(4):332–338.
   PubMed Web of Science ®Google Scholar
• Han MK. Chronic obstructive pulmonary disease in women: a biologically focused review with a systematic search strategy. Int J Chron Obstruct Pulmon Dis. 2020;15:711–721.
   PubMed Web of Science ®Google Scholar
• Antuni JD, Barnes PJ. Evaluation of individuals at risk for COPD: beyond the scope of the Global Initiative for Chronic Obstructive Lung Disease. Chronic Obstr Pulm Dis. 2016;3(3):653–667.
   PubMed Web of Science ®Google Scholar
• Breyer MK, Rutten EP, Vernooy JH, et al. Gender differences in the adipose secretome system in chronic obstructive pulmonary disease (COPD): a pivotal role of leptin. Respir Med. 2011;105(7):1046–1053.
   PubMed Web of Science ®Google Scholar
• Gut-Gobert C, Cavaillès A, Dixmier A, et al. Women and COPD: do we need more evidence? Eur Respir Rev. 2019;28(151):180055.
   PubMed Web of Science ®Google Scholar
• Legato MJ, Nepal SK, Aryal S. Gender differences in chronic obstructive pulmonary disease - current knowledge and deficits. In: Legato MJ, editor. Principles of Gender-Specific Medicine—Gender in the Genomic Era. 3rd Edn ed. Cambridge: Academic Press; 2017. p. 391–400.
   Google Scholar
• Celli B, Vestbo J, Jenkins CR, et al. Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease. The TORCH experience. Am J Respir Crit Care Med. 2011;183(3):317–322.
   PubMed Web of Science ®Google Scholar
• Perez TA, Castillo EG, Ancochea J, et al. Sex differences between women and men with COPD: a new analysis of the 3CIA study. Respir Med. 2020;171:106105.
   PubMed Web of Science ®Google Scholar
• Matera MG, Calzetta L, Rinaldi B, et al. Treatment of COPD: moving beyond the lungs. Curr Opin Pharmacol. 2012;12(3):315–322.
   PubMed Web of Science ®Google Scholar
• Grabicki M, Kuźnar-Kamińska B, Rubinsztajn R, et al. COPD course and comorbidities: are there gender differences? Adv Exp Med Biol. 2019;1113:43–51.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Bettoncelli G, Sessa E, et al. Prevalence of comorbidities in patients with chronic obstructive pulmonary disease. Respiration. 2010;80(2):112–119.
   PubMed Web of Science ®Google Scholar
• Sawalha S, Hedman L, Backman H, et al. The impact of comorbidities on mortality among men and women with COPD: report from the OLIN COPD study. Ther Adv Respir Dis. 2019;13:1753466619860058.
   Web of Science ®Google Scholar
• Lisspers K, Larsson K, Janson C, et al. Gender differences among Swedish COPD patients: results from the ARCTIC, a real-world retrospective cohort study. NPJ Prim Care Respir Med. 2019;29(1):45.
   PubMedGoogle Scholar
• Loganathan RS, Stover DE, Shi W, et al. Prevalence of COPD in women compared to men around the time of diagnosis of primary lung cancer. Chest. 2006;129(5):1305–1312.
   PubMed Web of Science ®Google Scholar
• Nagasaka M, Lehman A, Chlebowski R, et al. COPD and lung cancer incidence in the women’s health initiative observational study: a brief report. Lung Cancer. 2020;141:78–81.
   PubMed Web of Science ®Google Scholar
• Rabbani G, Shariful Islam SM, Rahman MA, et al. Pre-existing COPD is associated with an increased risk of mortality and severity in COVID-19: a rapid systematic review and meta-analysis. Expert Rev Respir Med. 2021. DOI:10.1080/17476348.2021.1866547.
   PubMed Web of Science ®Google Scholar
• Raparelli V, Palmieri L, Canevelli M, et al. Sex differences in clinical phenotype and transitions of care among individuals dying of COVID-19 in Italy. Biol Sex Differ. 2020;11(1):57. .
   PubMed Web of Science ®Google Scholar
• Franconi F, Brunelleschi S, Steardo L, et al. Gender differences in drug responses. Pharmacol Res. 2007;55(2):81–95.
   PubMed Web of Science ®Google Scholar
• Franconi F, Campesi I. Sex and gender influences on pharmacological response: an overview. Expert Rev Clin Pharmacol. 2014;7(4):469–485.
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease. Global strategy for prevention, diagnosis and management of COPD. 2021 Available at: https://goldcopd.org/wp-content/uploads/2020/11/GOLD-REPORT-2021-v1.0-16Nov20_WMV.pdf
   Google Scholar
• Torchalla I, Okoli CT, Bottorff JL, et al. Smoking cessation programs targeted to women: a systematic review. Women Health. 2012;52(1):32–54. .
   PubMed Web of Science ®Google Scholar
• Verplaetse TL, Morris ED, McKee SA, et al. Sex differences in the nicotinic acetylcholine and dopamine receptor systems underlying tobacco smoking addiction. Curr Opin Behav Sci. 2018;23:196–202.
   PubMed Web of Science ®Google Scholar
• Cosgrove KP, Esterlis I, Sandiego C, et al. Imaging tobacco smoking with PET and SPECT. Curr Top Behav Neurosci. 2015;24:1–17.
   PubMedGoogle Scholar
• Perkins KA. Smoking cessation in women. Special considerations. CNS Drugs. 2001;15(5):391–411.
   PubMed Web of Science ®Google Scholar
• Scanlon PD, Connett JE, Waller LA, et al. Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Health Study. Am J Respir Crit Care Med. 2000;161(2 Pt 1):381–390.
   PubMed Web of Science ®Google Scholar
• Hartmann-Boyce J, Chepkin SC, Ye W, et al. Nicotine replacement therapy versus control for smoking cessation. Cochrane Database Syst Rev. 2018;5(5):CD000146.
   PubMedGoogle Scholar
• Cepeda-Benito A, Reynoso JT, Erath S. Meta-analysis of the efficacy of nicotine replacement therapy for smoking cessation: differences between men and women. J Consult Clin Psychol. 2004;72(4):712–722.
   PubMed Web of Science ®Google Scholar
• Benowitz NL, Lessov-Schlaggar CN, Swan GE, et al. Female sex and oral contraceptive use accelerate nicotine metabolism. Clin Pharmacol Ther. 2006;79(5):480–488.
   PubMed Web of Science ®Google Scholar
• Yamanaka H, Nakajima M, Fukami T, et al. CYP2A6 AND CYP2B6 are involved in nornicotine formation from nicotine in humans: interindividual differences in these contributions. Drug Metab Dispos. 2005;33(12):1811–1818.
   PubMed Web of Science ®Google Scholar
• Benowitz NL. Nicotine addiction. N Engl J Med. 2010;362(24):2295–2303.
   PubMed Web of Science ®Google Scholar
• Pauly JR. Gender differences in tobacco smoking dynamics and the neuropharmacological actions of nicotine. Front Biosci. 2008;13(13):505–516.
   PubMedGoogle Scholar
• Coe JW, Brooks PR, Vetelino MG, et al. Varenicline: an α4β2 nicotinic receptor partial agonist for smoking cessation. J Med Chem. 2005;48(10):3474–3477.
   PubMed Web of Science ®Google Scholar
• Smith PH, Weinberger AH, Zhang J, et al. Sex differences in smoking cessation pharmacotherapy comparative efficacy: a Network Meta-analysis. Nicotine Tob Res. 2017;19(3):273–281.
   PubMed Web of Science ®Google Scholar
• Killen JD, Fortmann SP, Murphy GMJ, et al. Extended treatment with bupropion SR for cigarette smoking cessation. J Consult Clin Psychol. 2006;74(2):286–294.
   PubMed Web of Science ®Google Scholar
• Wileyto EP, Patterson F, Niaura R, et al. Recurrent event analysis of lapse and recovery in a smoking cessation clinical trial using bupropion. Nicotine Tob Res. 2005;7(2):257–268.
   PubMed Web of Science ®Google Scholar
• Lerman C, Shields PG, Wileyto EP, et al. Pharmacogenetic investigation of smoking cessation treatment. Pharmacogenetics. 2002;12(8):627–634.
   PubMedGoogle Scholar
• Swan GE, Valdes AM, Ring HZ, et al. Dopamine receptor DRD2 genotype and smoking cessation outcome following treatment with bupropion SR. Pharmacogenomics J. 2005;5(1):21–29.
   PubMed Web of Science ®Google Scholar
• Markle JG, Fish EN. SeXX matters in immunity. Trends Immunol. 2014;35(3):97–104.
   PubMed Web of Science ®Google Scholar
• Klein SL, Marriott I, Fish EN. Sex-based differences in immune function and responses to vaccination. Trans R Soc Trop Med Hyg. 2015;109(1):9–15.
   PubMed Web of Science ®Google Scholar
• Flanagan KL, Fink AL, Plebanski M, et al. Sex and gender differences in the outcomes of vaccination over the life course. Annu Rev Cell Dev Biol. 2017;33(1):577–599.
   PubMed Web of Science ®Google Scholar
• Cook IF. Sexual dimorphism of humoral immunity with human vaccines. Vaccine. 2008;26(29–30):3551–3555.
   PubMed Web of Science ®Google Scholar
• Engler RJ, Nelson MR, Klote MM, et al. Half- vs full-dose trivalent inactivated influenza vaccine (2004-2005): age, dose, and sex effects on immune responses. Arch Intern Med. 2008;168(22):2405–2414.
   PubMedGoogle Scholar
• Fink AL, Engle K, Ursin RL, et al. Biological sex affects vaccine efficacy and protection against influenza in mice. Proc Natl Acad Sci U S A. 2018;115(49):12477–12482.
   PubMed Web of Science ®Google Scholar
• Potluri T, Fink AL, Sylvia KE, et al., Age-associated changes in the impact of sex steroids on influenza vaccine responses in males and females. Npj Vaccines. 4(1): 29. 2019 .
   PubMedGoogle Scholar
• Cook IF. Sex differences in injection site reactions with human vaccines. Hum Vaccin. 2009;5(7):441–449.
   PubMed Web of Science ®Google Scholar
• Brandão AP, de Oliveira TC, de Cunto Brandileone MC, et al. Persistence of antibody response to pneumococcal capsular polysaccharides in vaccinated long term-care residents in Brazil. Vaccine. 2004;23(6):762–768.
   PubMed Web of Science ®Google Scholar
• Goldblatt D, Southern J, Andrews N, et al. The immunogenicity of 7-valent pneumococcal conjugate vaccine versus 23-valent polysaccharide vaccine in adults aged 50-80 years. Clin Infect Dis. 2009;49(9):1318–1325.
   PubMed Web of Science ®Google Scholar
• Boef AGC, FRM VDK, Berbers GAM, et al. Differences by sex in IgG levels following infant and childhood vaccinations: an individual participant data meta-analysis of vaccination studies. Vaccine. 2018;36(3):400–407.
   PubMed Web of Science ®Google Scholar
• Bermal N, Szenborn L, Chrobot A, et al. The 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) coadministered with DTPw-HBV/Hib and poliovirus vaccines: assessment of immunogenicity. Pediatr Infect Dis J. 2009;28(4 Suppl):S89–S96.
   PubMed Web of Science ®Google Scholar
• Sankilampi U, Isoaho R, Bloigu A, et al. Effect of age, sex and smoking habits on pneumococcal antibodies in an elderly population. Int J Epidemiol. 1997;26(2):420–427.
   PubMed Web of Science ®Google Scholar
• Lopez Varela MV. Montes de Oca M, Halbert RJ, et al. Sex-related differences in COPD in five Latin American cities: the PLATINO study. Eur Respir J. 2010;36(5):1034–1041.
   PubMed Web of Science ®Google Scholar
• Anthonisen NR, Lindgren PG, Tashkin DP, et al. Bronchodilator response in the lung health study over 11 yrs. Eur Respir J. 2005;26(1):45–51.
   PubMed Web of Science ®Google Scholar
• Bhallamudi S, Connell J, Pabelick CM, et al. Estrogen receptors differentially regulate intracellular calcium handling in human nonasthmatic and asthmatic airway smooth muscle cells. Am J Physiol Lung Cell Mol Physiol. 2020;318(1):L112–L124.
   PubMed Web of Science ®Google Scholar
• Triebner K, Matulonga B, Johannessen A, et al. Menopause is associated with accelerated lung function decline. Am J Respir Crit Care Med. 2017;195(8):1058–1065.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Puxeddu E, Bettoncelli G, et al. The prevalence of asthma and COPD in Italy: a practice-based study. Respir Med. 2011;105(3):386–391.
   PubMed Web of Science ®Google Scholar
• Kamil F, Pinzon I, Foreman MG. Sex and race factors in early-onset COPD. Curr Opin Pulm Med. 2013;19(2):140–144.
   PubMed Web of Science ®Google Scholar
• Foster PS, Goldie RG, Paterson JW. Effect of steroids on beta-adrenoceptor-mediated relaxation of pig bronchus. Br J Pharmacol. 1983;78(2):441–445.
   PubMed Web of Science ®Google Scholar
• Bordallo J, de Boto MJ, Meana C, et al. Modulatory role of endogenous androgens on airway smooth muscle tone in isolated guinea-pig and bovine trachea; involvement of beta2-adrenoceptors, the polyamine system and external calcium. Eur J Pharmacol. 2008;601(1–3):154–162.
   PubMed Web of Science ®Google Scholar
• Suárez L, Pipa M, Granda J, et al. Sex hormones modulate salbutamol-elicited long-term relaxation in isolated bovine tracheal strips. Pharmacology. 2011;87(5–6):249–256.
   PubMed Web of Science ®Google Scholar
• Carbajal-García A, Reyes-García J, Casas-Hernández MF, et al. Testosterone augments β2 adrenergic receptor genomic transcription increasing salbutamol relaxation in airway smooth muscle. Mol Cell Endocrinol. 2020;510:110801.
   PubMed Web of Science ®Google Scholar
• Carbajal-García A, Reyes-García J, Montaño LM. Androgen effects on the adrenergic system of the vascular, airway, and cardiac myocytes and their relevance in pathological processes. Int J Endocrin. 2020;2020:8849641.
   PubMed Web of Science ®Google Scholar
• Lima JJ, Mohamed MH, Self TH, et al. Importance of beta2 adrenergic receptor genotype, gender and race on albuterol-evoked bronchodilation in asthmatics. Pulm Pharmacol Ther. 2000;13(3):127–134.
   PubMed Web of Science ®Google Scholar
• Vestbo J, Soriano JB, Anderson JA, et al. Gender does not influence the response to the combination of salmeterol and fluticasone propionate in COPD. Respir Med. 2004;98(11):1045–1050.
   PubMed Web of Science ®Google Scholar
• Li X, Obeidat M, Zhou G, et al. Responsiveness to ipratropium bromide in male and female patients with mild to moderate chronic obstructive pulmonary disease. EBioMedicine. 2017;19:139–145.
   PubMed Web of Science ®Google Scholar
• Tashkin D, Celli B, Kesten S, et al. Effect of tiotropium in men and women with COPD: results of the 4-year UPLIFT trial. Respir Med. 2010;104(10):1495–1504.
   PubMed Web of Science ®Google Scholar
• Ohar JA, Ozol-Godfrey A, Goodin T, et al. Effect of gender on lung function and patient-reported outcomes in patients with COPD receiving nebulized glycopyrrolate. Int J Chron Obstruct Pulmon Dis. 2020;15:995–1004.
   PubMed Web of Science ®Google Scholar
• Leidy NK, Murray LT. Patient-reported outcome (PRO) measures for clinical trials of COPD: the EXACT and E-RS. COPD. 2013;10(3):393–398.
   PubMedGoogle Scholar
• Tsiligianni I, Mezzi K, Fucile S, et al. Response to indacaterol/glycopyrronium (IND/GLY) by sex in patients with COPD: a pooled analysis from the IGNITE program. COPD. 2017;14(4):375–381.
   PubMedGoogle Scholar
• Nafziger AN, Bertino JS Jr. Sex-related differences in theophylline pharmacokinetics. Eur J Clin Pharmacol. 1989;37(1):97–100.
   PubMed Web of Science ®Google Scholar
• Rasmussen BB, Brøsen K. Determination of urinary metabolites of caffeine for the assessment of cytochrome P4501A2, xanthine oxidase, and N-acetyltransferase activity in humans. Ther Drug Monit. 1996;18(3):254–262.
   PubMed Web of Science ®Google Scholar
• Gardner MJ, Schatz M, Cousins L, et al. Longitudinal effects of pregnancy on the pharmacokinetics of theophylline. Eur J Clin Pharmacol. 1987;32(3):289–295.
   PubMed Web of Science ®Google Scholar
• Zaigler M, Rietbrock S, Szymanski J, et al. Variation of CYP1A2-dependent caffeine metabolism during menstrual cycle in healthy women. Int J Clin Pharmacol Ther. 2000;38(5):235–244.
   PubMed Web of Science ®Google Scholar
• Kroon J, Pereira AM, Meijer OC. Glucocorticoid sexual dimorphism in metabolism: dissecting the role of sex hormones. Trends Endocrinol Metab. 2020;31(5):357–367.
   PubMed Web of Science ®Google Scholar
• Duma D, Collins JB, Chou JW, et al. Sexually dimorphic actions of glucocorticoids provide a link to inflammatory diseases with gender differences in prevalence. Sci Signal. 2010;3(143):ra74.
   PubMed Web of Science ®Google Scholar
• Watson L, Schouten JP, Löfdahl CG, et al. Predictors of COPD symptoms: does the sex of the patient matter? Eur Respir J. 2006;28(2):311–318.
   PubMed Web of Science ®Google Scholar
• Schermer TR, Hendriks AJ, Chavannes NH, et al. Probability and determinants of relapse after discontinuation of inhaled corticosteroids in patients with COPD treated in general practice. Prim Care Respir J. 2004;13(1):48–55.
   PubMedGoogle Scholar
• Liu SF, Kuo HC, Liu GH, et al. Inhaled corticosteroids can reduce osteoporosis in female patients with COPD. Int J Chron Obstruct Pulmon Dis. 2016;11:1607–1614.
   PubMed Web of Science ®Google Scholar
• Chen W, Johnson KM, FitzGerald JM, et al. Long-term effects of inhaled corticosteroids on bone mineral density in older women with asthma or COPD: a registry-based cohort study. Arch Osteoporos. 2018;13(1):116.
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Singh D, Tsiligianni I, et al., Treatment response to indacaterol/glycopyrronium versus salmeterol/fluticasone in exacerbating COPD patients by gender: a post-hoc analysis in the FLAME study. Respir Res. 20(1): 4. 2019.
   PubMedGoogle Scholar
• Huang J, Fu CX, Yang XY, et al. Pharmacokinetics of single- and multiple-dose roflumilast: an open-label, three-way crossover study in healthy Chinese volunteers. Drug Des Devel Ther. 2018;12:4047–4057.
   PubMed Web of Science ®Google Scholar
• Yu T, Fain K, Boyd CM, et al. Benefits and harms of roflumilast in moderate to severe COPD. Thorax. 2014;69(7):616–622.
   PubMed Web of Science ®Google Scholar
• Martinez FJ, Rabe KF, Calverley PMA, et al. Determinants of response to roflumilast in severe chronic obstructive pulmonary disease. Pooled analysis of two randomized trials. Am J Respir Crit Care Med. 2018;198(10):1268–1278.
   PubMed Web of Science ®Google Scholar
• Albert RK, Connett J, Bailey WC, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med. 2011;365(8):689–698.
   PubMed Web of Science ®Google Scholar
• Han MK, Tayob N, Murray S, et al. Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy. Am J Respir Crit Care Med. 2014;189(12):1503–1508.
   PubMed Web of Science ®Google Scholar
• Rogliani P, Ora J, Puxeddu E, et al. Adherence to COPD treatment: myth and reality. Respir Med. 2017;129:117–123.
   PubMed Web of Science ®Google Scholar
• Ágh T, Inotai A, Mészáros Á. Factors associated with medication adherence in patients with chronic obstructive pulmonary disease. Respiration. 2011;82(4):328–334.
   PubMed Web of Science ®Google Scholar
• Jarab AS, Mukattash TL. Exploring variables associated with medication non-adherence in patients with COPD. Int J Clin Pharm. 2019;41(5):1202–1209.
   PubMed Web of Science ®Google Scholar
• Dales RE, Mehdizadeh A, Aaron SD, et al. Sex differences in the clinical presentation and management of airflow obstruction. Eur Respir J. 2006;28(2):319–322.
   PubMed Web of Science ®Google Scholar
• Mueller S, Wilke T, Bechtel B, et al. Non-persistence and non-adherence to long-acting COPD medication therapy: a retrospective cohort study based on a large German claims dataset. Respir Med. 2017;122:1–11.
   PubMed Web of Science ®Google Scholar
• Goodman DE, Israel E, Rosenberg M, et al. The influence of age, diagnosis, and gender on proper use of metered-dose inhalers. Am J Respir Crit Care Med. 1994;150(5 Pt 1):1256–1261.
   PubMed Web of Science ®Google Scholar
• Sestini P, Cappiello V, Aliani M, et al. Prescription bias and factors associated with improper use of inhalers. J Aerosol Med. 2006;19(2):127–136.
   PubMedGoogle Scholar
• Cazzola M, Cavalli F, Usmani OS, et al. Advances in pulmonary drug delivery devices for the treatment of chronic obstructive pulmonary disease. Expert Opin Drug Deliv. 2020;17(5):635–646.
   PubMed Web of Science ®Google Scholar
• Malmberg LP, Rytilä P, Happonen P, et al. Inspiratory flows through dry powder inhaler in chronic obstructive pulmonary disease: age and gender rather than severity matters. Int J Chron Obstruct Pulmon Dis. 2010;5:257–262.
   PubMedGoogle Scholar
• Clini E, Costi S, Lodi S, et al. Non-pharmacological treatment for chronic obstructive pulmonary disease. Med Sci Monit. 2003;9(12):RA300–305.
   PubMedGoogle Scholar
• Miyamoto K, Aida A, Nishimura M, et al. Gender effect on prognosis of patients receiving long-term home oxygen therapy. The Respiratory Failure Research Group in Japan. Am J Respir Crit Care Med. 1995;152(3):972–976.
   PubMed Web of Science ®Google Scholar
• Crockett AJ, Cranston JM, Moss JR, et al. Survival on long-term oxygen therapy in chronic airflow limitation: from evidence to outcomes in the routine clinical setting. Intern Med J. 2001;31(8):448–454.
   PubMed Web of Science ®Google Scholar
• Coleta KD, Lima DF, Tanni SE, et al. Gender and health status response to long-term oxygen therapy in COPD patients. Arch Bronconeumol. 2011;47(8):382–388.
   PubMed Web of Science ®Google Scholar
• Machado M-CL, Krishnan JA, Buist SA, et al. Sex differences in survival of oxygen-dependent patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2006;174(5):524–529.
   PubMed Web of Science ®Google Scholar
• Robles PG, Brooks D, Goldstein R, et al. Gender-associated differences in pulmonary rehabilitation outcomes in people with chronic obstructive pulmonary disease: a systematic review. J Cardiopulm Rehabil Prev. 2014;34(2):87–97.
   PubMed Web of Science ®Google Scholar
• Spielmanns M, Gloeckl R, Schmoor C, et al. Effects on pulmonary rehabilitation in patients with COPD or ILD: a retrospective analysis of clinical and functional predictors with particular emphasis on gender. Respir Med. 2016;113:8–14.
   PubMed Web of Science ®Google Scholar
• Grosbois JM, Gephine S, Diot AS, et al. Gender does not impact the short- or long-term outcomes of home-based pulmonary rehabilitation in patients with COPD. ERJ Open Res. 2020;6(4):00032–2020.
   PubMedGoogle Scholar
• Barnes PJ. Sex differences in chronic obstructive pulmonary disease mechanisms. Am J Respir Crit Care Med. 2016;193(8):813–814.
   PubMed Web of Science ®Google Scholar
• Nici L, Mammen MJ, Charbek E, et al., Pharmacologic management of chronic obstructive pulmonary disease. An official American Thoracic Society clinical practice guideline. Am J Respir Crit Care Med. 201(9): e56–e69. 2020.
   PubMed Web of Science ®Google Scholar
• Rinne ST, Elwy AR, Liu CF, et al. Implementation of guideline-based therapy for chronic obstructive pulmonary disease: differences between men and women veterans. Chron Respir Dis. 2017;14(4):385–391.
   PubMed Web of Science ®Google Scholar
• Bade BC, DeRycke EC, Ramsey C, et al. Sex differences in veterans admitted to the hospital for chronic obstructive pulmonary disease exacerbation. Ann Am Thorac Soc. 2019;16(6):707–714.
   PubMed Web of Science ®Google Scholar
• Sundh J, Åberg J, Hasselgren M, et al. Factors influencing pharmacological treatment in COPD: a comparison of 2005 and 2014. Eur Clin Respir J. 2017;4(1):1409060.
   PubMed Web of Science ®Google Scholar
• Åberg J, Hasselgren M, Montgomery S, et al. Sex-related differences in management of Swedish patients with a clinical diagnosis of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2019;14:961–969.
   PubMed Web of Science ®Google Scholar
• Jia G, Lu M, Wu R, et al. Gender difference on the knowledge, attitude, and practice of COPD diagnosis and treatment: a national, multicenter, cross-sectional survey in China. Int J Chron Obstruct Pulmon Dis. 2018;13:3269–3280.
   PubMed Web of Science ®Google Scholar
• Isgrò V, Sultana J, Fontana A, et al., Gender differences in COPD management in a Sicilian general practice setting: a cohort study evaluating the impact of educational interventions. ERJ Open Res. 6(3): 00279–2020. 2020.
   PubMedGoogle Scholar
• Oshagbemi OA, Burden AM, Braeken DCW, et al. Stability of blood eosinophils in patients with chronic obstructive pulmonary disease and in control subjects, and the impact of sex, age, smoking, and baseline counts. Am J Respir Crit Care Med. 2017;195(10):1402–1404.
   PubMed Web of Science ®Google Scholar
• Hong Y, Ji W, An S, et al. Sex differences of COPD phenotypes in nonsmoking patients. Int J Chron Obstruct Pulmon Dis. 2016;11:1657–1662.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Calzetta L, Rogliani P, et al. The challenges of precision medicine in COPD. Mol Diagn Ther. 2017;21(4):345–355.
   PubMed Web of Science ®Google Scholar
• Matera MG, Cardaci V, Cazzola M, et al. Safety of inhaled corticosteroids for treating chronic obstructive pulmonary disease. Expert Opin Drug Saf. 2015;14(4):533–541.
   PubMed Web of Science ®Google Scholar